- RecruitingPHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This study looks at new treatments for stomach or food pipe cancer that can be removed by surgery. It aims to see how safe and effective these new drugs or drug combinations are before and after the operation.
For: Gastroesophageal AdenocarcinomaUnited States · Canada · China - RecruitingPHASE1
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
This study is testing a new combination treatment for stomach or gullet cancer that can be removed with surgery. It combines a drug called Tislelizumab with standard chemotherapy (FLOT) given before the operation. We want to see if this new approach is safe and works well.
For: Esophagogastric Junction Adenocarcinoma · Gastric Adenocarcinoma · Esophageal AdenocarcinomaGermany - Active not recruitingPHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This study looks at a new drug, durvalumab, and standard chemotherapy (FLOT) for stomach or food pipe cancer that can be removed by surgery. It aims to see if this combination, given before and after the operation, is safe and effective.
For: Gastrointestinal Neoplasms · Esophagogastric JunctionUnited States · Argentina · Belgium